9.5.2.1 Phosphate supplements
Phosphate-Sandoz
(Sodium acid phosphate anhydrous)
- Effervescent tablets 1.936g (£19.39 = 100 tablets)
Indication
- Vitamin D-resistant hypophosphataemic osteomalacia
Dose
- 4–6 tablets daily; child under 5 years 2–3 tablets daily
Notes
- Medicines Supply Notification (22 December 2023): Phosphate Sandoz (sodium dihydrogen phosphate anhydrous 1.936g) effervescent tablets
- Phosphate Sandoz effervescent tablets are in limited supply until late March 2024.
- For further information, refer to the notification.
Mixed phosphates
- Solution 0.5 mmol/ml (unlicensed preparation)
Phosphates
Potassium phosphates
- Injection 17.42% 10ml (unlicensed preparation)
9.5.2.2 Phosphate-binding agents
Calcium
Drugs used not listed here:
Phosex
(Calcium acetate)
- Tablets 1g (£19.79 = 180 tablets)
- Tablets 500mg (unlicensed preparation)
Indications
Dose
- Initially 1 tablet 3 times daily with meals, adjusted according to serum-phosphate concentration (usual dose 4–6 tablets daily); maximum 12 tablets daily
Notes
- Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Renacet
(Calcium acetate)
- Tablets 475mg, 950mg (£14.95 = 200 x 475mg tablets)
Indications
Dose
- 475–950mg, to be taken with breakfast and with snacks, 0.95–2.85g, to be taken with main meals and 0.95–1.9g, to be taken with supper, dose to be adjusted according to serum-phosphate concentration; maximum 6.65g per day.
Notes
- Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Osvaren
(calcium acetate with magnesium carbonate)
- Tablets (435mg + 235mg) (£24.00 = 180 tablets)
Indications
Dose
- Initially 1 tablet 3 times daily with meals, adjusted according to serum-phosphate concentration (usual dose 3–10 tablets daily); maximum 12 tablets daily
Notes
- Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Lanthanum carbonate
- Chewable tablets 500mg, 750mg, 1g (£182.60 = 90 x 750mg tablets)
Indications
Dose
- Usual dose range 1.5–3g daily in divided doses with or immediately after meals, adjusted according to serum-phosphate concentration every 2–3 weeks
Sevelamer hydrochloride
- Renagel tablets 800mg (£167.04 = 180 tablets)
Indications
Dose
- Initially 2.4–4.8g daily in 3 divided doses with meals, adjusted according to serum-phosphate concentration (usual dose range 2.4–12g daily in 3 divided doses)
Sevelamer carbonate
- Tablets 800mg (£31.38 = 180 tablets)
Indications
Dose
- Usual dose approximately 6g daily in 3 divided doses
Notes
- Sevelamer carbonate is not interchangeable with sevelamer hydrochloride. When prescribing please include the correct salt.
- Sevelamer carbonate is licensed for both dialysis and non-dialysis patients.
Sucroferric oxyhydroxide
Indications
- Hyperphosphataemia in adult patients with chronic kidney disease on haemodialysis or peritoneal dialysis (NHS England commissioned)
Notes
- Tablets must be chewed or crushed, not swallowed whole
9.5.2.3 Burosumab
Burosumab
- Solution for injection vials 10mg/1ml, 20mg/1ml, 30mg/1ml
Notes
- NICE HST8: Burosumab (Crysvita) is recommended, within its marketing authorisation, for treating X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in babies, children and young people 1 to 17 years, only if the company provides it according to the commercial arrangement (October 2018, updated September 2024).
- NICE TA993: Burosumab (Crysvita) is recommended, within its marketing authorisation, as an option for treating X-linked hypophosphataemia (XLH) in adults, only if the company provides it according to the commercial arrangement (August 2024).